Immunotherapy Special Issue 2019 | CURE

October 02, 2019

An early clinical trial participant likens his journey into the unknown to a space mission.

October 02, 2019

A man who received chimeric antigen receptor-T cell therapy shares his firsthand account.

October 01, 2019

Although there is much to learn about the intricacies of how the immune system interacts with cancer, advances are occurring rapidly as immunotherapy for cancer has exploded with myriad ongoing clinical trials and newer drugs coming on line constantly.

September 30, 2019

In this special issue of CURE®, we take a walk through history, from revisiting the major medical milestones of immunotherapy to reviewing how far it has come in cancer treatment.

September 27, 2019

Treatment with Opdivo (nivolumab) plus Yervoy (ipilimumab) led to a 44% response rate in patients with high-grade neuroendocrine tumors, according to phase 2 study findings.

September 27, 2019

Immunotherapy medications have been a wonderful addition to the arsenal of cancer therapeutics. Their use has revolutionized the treatment of many cancers and offers new hope to patients. However, these upsides do not come without downsides.

September 26, 2019

Cutting-edge treatment is not out of reach, thanks to a little guidance from the Cancer Research Institute.

September 25, 2019

A look back at how immunotherapy began in oncology.

September 24, 2019

For some patients with melanoma, eating a diet rich in fiber could lead to an improved response to immunotherapy, according to findings presented at this year’s American Association for Cancer Research annual meeting.

September 24, 2019

As immunotherapies emerge in the treatment of liver cancer, experts examine whether two or more is better than one.

September 23, 2019

Immunotherapy takes on a new role in treating patients with triple-negative disease.